IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation

• Published in: Blood cancer discovery 2024-03, Vol.5 (2), p.114-131
• Main Authors: Landberg, Niklas, Köhnke, Thomas, Feng, Yang, Nakauchi, Yusuke, Fan, Amy C, Linde, Miles H, Karigane, Daiki, Lim, Kelly, Sinha, Rahul, Malcovati, Luca, Thomas, Daniel, Majeti, Ravindra
• Format: Article
• Language: English
• Subjects: Hematological Cancers; Metabolism; Stem Cell Biology
• ISSN: 2643-3230; 2643-3249; 2643-3249
• DOI: 10.1158/2643-3230.BCD-23-0195

Rare preleukemic hematopoietic stem cells (pHSCs) harboring only the initiating mutations can be detected at the time of AML diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene-editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSCs). We confirm that IDH1 driven clonal hematopoiesis is associated with cytopenia, suggesting an inherent defect to fully reconstitute hematopoiesis. Despite giving rise to multilineage engraftment, IDH1-mutant pHSCs exhibited reduced proliferation, blocked differentiation, downregulation of MHC Class II genes, and reprogramming of oxidative phosphorylation metabolism. Critically, inhibition of oxidative phosphorylation resulted in complete eradication of IDH1-mutant pHSCs but not IDH2-mutant pHSCs or wildtype HSCs. Our results indicate that IDH1-mutant preleukemic clones can be targeted with complex I inhibitors, offering a potential strategy to prevent development and relapse of leukemia.